Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098–1105.

On page 1099 of the February 4, 2010, issue, in the fifth sentence under the heading “Clinical trial” in “Methods,” the authors overlooked the inclusion of an important criterion they used to define thrombotic microangiopathy TMA. The published text read: “TMA was defined as the simultaneous occurrence of schistocytosis, increased lactate dehydrogenase, and persistent thrombocytopenia (below 50 000/μL).” The sentence should have read: “TMA was defined as the simultaneous occurrence of schistocytosis, increased lactate dehydrogenase, persistent thrombocytopenia (below 50 000/μL), and elevated serum Cr more than 1.5 times the pretransplantation baseline.”